Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

被引：0
|
作者：
Vu, Ravi [1 ]
Wang, Michael [2 ]
Orlowski, Robert [2 ]
Stewart, A. Keith [3 ]
Jagannath, Sundar [4 ]
Kukreti, Vishal [5 ]
Taylor, Jessica [6 ]
Fuhrman, Diana [6 ]
Cruickshank, Scott [6 ]
Schwartz, Richard [6 ]
Kunkel, Lori [6 ]
Siegel, David [7 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mayo Clin, Scottsdale, AZ USA
[4] St Vincents Comp Canc Ctr, New York, NY USA
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Proteolix Inc, Clin Operat, San Francisco, CA USA
[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[8] MMRC, Norwalk, CT USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：320 / 320
页数：1
相关论文
共 50 条
  • [21] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
  • [22] Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
    Quach, Hang
    White, Darrell
    Spencer, Andrew
    Ho, P. Joy
    Bhutani, Divaya
    White, Mike
    Inamdar, Sandeep
    Morris, Chris
    Ou, Ying
    Gyger, Martin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1067 - 1076
  • [23] Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
    Hang Quach
    Darrell White
    Andrew Spencer
    P. Joy Ho
    Divaya Bhutani
    Mike White
    Sandeep Inamdar
    Chris Morris
    Ying Ou
    Martin Gyger
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1067 - 1076
  • [24] An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    Vij, Ravi
    Siegel, David S.
    Jagannath, Sundar
    Jakubowiak, Andrzej J.
    Stewart, Alexander Keith
    McDonagh, Kevin
    Bahlis, Nizar
    Belch, Andrew
    Kunkel, Lori A.
    Wear, Sandra
    Wong, Alvin F.
    Orlowski, Robert Z.
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 739 - 748
  • [25] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
    Schwartzberg, Lee
    Hermann, Robert
    Flinn, Ian
    Flora, Douglas
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Myrand, Scott P.
    Nguyen, Tuan S.
    Dreyling, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
  • [26] An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)
    Quach, Hang
    White, Darrell
    Spencer, Andrew
    Ho, P. Joy
    Bhutani, Divaya
    White, Mike
    Inamdar, Sandeep
    Morris, Chris
    Ou, Ying
    Gyger, Martin
    BLOOD, 2016, 128 (22)
  • [27] Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R M/M)
    Vij, R.
    Siegel, D. S.
    Kaufman, J. L.
    Jakubowiak, A. J.
    Stewart, A. K.
    Jagannath, S.
    Kukreti, V.
    Le, M. H.
    Bennett, M. K.
    Wang, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma
    Browning, Sabrina
    Li, Fangyong
    Parker, Terri L.
    Bar, Noffar
    Anderson, Tara
    Stevens, Erica
    VanOudenhove, Jennifer
    Matthews, Martin
    Gorshein, Elan
    Talsania, Ashita D.
    Sabbath, Kert D.
    Seropian, Stuart
    Halene, Stephanie
    Neparidze, Natalia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [30] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Gregory, Tara K.
    Matous, Jeffrey
    Hart, Lowell L.
    Owera, Rami
    Mace, Joseph Ronald
    Essell, James H.
    Flinn, Ian
    Faber, Edward Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345